loading
Schlusskurs vom Vortag:
$1.12
Offen:
$1.14
24-Stunden-Volumen:
156.41K
Relative Volume:
0.14
Marktkapitalisierung:
$8.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.63M
KGV:
-2.5805
EPS:
-0.43
Netto-Cashflow:
$-21.84M
1W Leistung:
+2.18%
1M Leistung:
-12.42%
6M Leistung:
-35.47%
1J Leistung:
-84.88%
1-Tages-Spanne:
Value
$1.075
$1.1499
1-Wochen-Bereich:
Value
$1.00
$1.22
52-Wochen-Spanne:
Value
$0.7233
$8.0985

Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile

Name
Firmenname
Brainstorm Cell Therapeutics Inc
Name
Telefon
201-488-0460
Name
Adresse
1325 AVENUE OF AMERICAS, NEW YORK, NY
Name
Mitarbeiter
29
Name
Twitter
@BrainStormCell
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
BCLI's Discussions on Twitter

Vergleichen Sie BCLI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BCLI
Brainstorm Cell Therapeutics Inc
1.11 8.57M 0 -16.63M -21.84M -0.43
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.06 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.65 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.40 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.11 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
501.32 65.13B 14.09B 4.50B 2.96B 39.28

Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-02-04 Hochstufung Maxim Group Hold → Buy
2020-11-17 Herabstufung Maxim Group Buy → Hold
2016-12-19 Bestätigt Maxim Group Buy
2015-12-22 Bestätigt Maxim Group Buy

Brainstorm Cell Therapeutics Inc Aktie (BCLI) Neueste Nachrichten

pulisher
May 30, 2025

What is Zacks Small Cap’s Estimate for BCLI FY2025 Earnings? - Defense World

May 30, 2025
pulisher
May 29, 2025

Q2 Earnings Estimate for BCLI Issued By Zacks Small Cap - Defense World

May 29, 2025
pulisher
May 28, 2025

BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

BrainStorm partners with Minaris for ALS therapy trial By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - Yahoo Finance

May 27, 2025
pulisher
May 27, 2025

BrainStorm partners with Minaris for ALS therapy trial - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for Nu - GuruFocus

May 27, 2025
pulisher
May 27, 2025

BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for NurOwn Manufacturing | BCLI Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

BrainStorm Accelerates NurOwn ALS Treatment Development Through Major Manufacturing Deal with Minaris - Stock Titan

May 27, 2025
pulisher
May 26, 2025

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell Lawsuit – BCLI - ACCESS Newswire

May 26, 2025
pulisher
May 23, 2025

FDA clears Phase 3b trial of NurOwn for ALS - ALS News Today

May 23, 2025
pulisher
May 22, 2025

Gene And Cell Therapies Targeting Cns Disorders Market in 2025 - openPR.com

May 22, 2025
pulisher
May 21, 2025

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World

May 21, 2025
pulisher
May 20, 2025

Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans - MSN

May 20, 2025
pulisher
May 20, 2025

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

May 20, 2025
pulisher
May 20, 2025

What Did We Note About Insider Trading At Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)? - Stocksregister

May 20, 2025
pulisher
May 20, 2025

FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment - Yahoo Finance

May 20, 2025
pulisher
May 19, 2025

Brainstorm Cell Therapeutics Reports Q1 2025 Financials - TipRanks

May 19, 2025
pulisher
May 19, 2025

BrainStorm advances ALS treatment with FDA trial nod By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

BrainStorm advances ALS treatment with FDA trial nod - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Sector Update: Health Care Stocks Advance Monday Afternoon - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Top Midday Gainers - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BrainStorm (BCLI) Options Delisting Announced | BCLI Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Earnings call transcript: BrainStorm Cell Therapeutics Q1 2025 sees stock surge after trial updates - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

Micro Cap Bid Up Aggressively On FDA Clearance Announcement - The Globe and Mail

May 19, 2025
pulisher
May 19, 2025

Transcript : Brainstorm Cell Therapeutics Inc., Q1 2025 Earnings Call, May 19, 2025 - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BrainStorm (BCLI) Receives FDA Green Light for NurOwn Phase 3b A - GuruFocus

May 19, 2025
pulisher
May 19, 2025

BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Breaking ALS Treatment News: FDA Gives Green Light to BrainStorm's Crucial Phase 3b NurOwn Trial - Stock Titan

May 19, 2025
pulisher
May 16, 2025

SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc. - Quantisnow

May 16, 2025
pulisher
May 16, 2025

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - StreetInsider

May 16, 2025
pulisher
May 16, 2025

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - PR Newswire

May 16, 2025
pulisher
May 16, 2025

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - The Malaysian Reserve

May 16, 2025
pulisher
May 15, 2025

SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc. - Quantisnow

May 15, 2025
pulisher
May 15, 2025

Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025
pulisher
May 15, 2025

BrainStorm Reschedules First Quarter 2025 Financial Results Rele - GuruFocus

May 15, 2025
pulisher
May 15, 2025

BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call - Stock Titan

May 15, 2025
pulisher
May 15, 2025

StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World

May 15, 2025
pulisher
May 13, 2025

Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Thursday - Defense World

May 13, 2025
pulisher
May 10, 2025

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - MSN

May 10, 2025
pulisher
May 09, 2025

Stem Cell Therapy Market 2025: Technical Signs Point Higher Growth Levels - newstrail.com

May 09, 2025
pulisher
May 08, 2025

SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 08, 2025
pulisher
May 06, 2025

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - Nasdaq

May 06, 2025
pulisher
May 06, 2025

BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Sells 630,315 Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Defense World

May 05, 2025
pulisher
May 01, 2025

5 Best Stem Cell Companies to Invest In (June 2025) - Securities.io

May 01, 2025
pulisher
Apr 30, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 30, 2025
pulisher
Apr 29, 2025

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell LawsuitBCLI - ACCESS Newswire

Apr 29, 2025
pulisher
Apr 29, 2025

BrainStorm's NurOwn® Data Selected as Breakthrough Science for P - GuruFocus

Apr 29, 2025

Finanzdaten der Brainstorm Cell Therapeutics Inc-Aktie (BCLI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Brainstorm Cell Therapeutics Inc-Aktie (BCLI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lebovits Chaim
President & CEO
Sep 30 '24
Buy
0.23
22,000
5,016
1,186,865
Dagher Ibrahim B.
Chief Medical Officer
Jul 19 '24
Sale
0.35
63,000
22,069
0
$1.0846
price down icon 1.76%
$29.97
price down icon 0.70%
$577.79
price up icon 0.89%
$306.27
price up icon 0.67%
$4.47
price down icon 2.22%
$489.50
price down icon 0.11%
Kapitalisierung:     |  Volumen (24h):